Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frej Fyhrquist

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of the American College of Cardiology|September 6, 2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) studyEigil Fossum, Andreas Moan, Sverre E Kjeldsen, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 24, 2005
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE studySverre E Kjeldsen, Paulette A Lyle, Jorge R Kizer, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 8, 2004
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyJorge R Kizer, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Journal of the American Heart Association|August 20, 2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β<sub>1</sub>-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)Sonal Singh, Helen R Warren, Timo P Hiltunen, et al.
Annals of Internal Medicine|December 4, 2003
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE studyKristian Wachtell, Hans Ibsen, Michael H Olsen, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of the American College of Cardiology|September 6, 2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) studyEigil Fossum, Andreas Moan, Sverre E Kjeldsen, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 24, 2005
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE studySverre E Kjeldsen, Paulette A Lyle, Jorge R Kizer, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 8, 2004
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyJorge R Kizer, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Journal of the American Heart Association|August 20, 2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β<sub>1</sub>-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)Sonal Singh, Helen R Warren, Timo P Hiltunen, et al.
Annals of Internal Medicine|December 4, 2003
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE studyKristian Wachtell, Hans Ibsen, Michael H Olsen, et al.
Pageof 6